Black Squad Classic NFT
The official minting begins !

Personalized Smart Healthcare Solution

logo.png

CDBIO PROTOCOL

Based on Molecular Diagnostics

555.png

ABOUT

Blockchain can meet the demands of healthcare

big data sharing process by enabling consensus

among untrusted parties, ensuring security

and granular data access.

 

CDBIO Molecular-Medical/Healthcare Platform

Mainnet’s Consortium blockchain includes universities,

research institutes, hospitals, pharmaceutical companies,

nsurance companies and consumer goods companies,

including partners in various health fields,

providing research and development activities

and services based on PGHD and EHR provided

by consumers and patients.

 

Medical & Healthcare
Services Platform

CDBIO's Molecular Medical & Healthcare Platform

consists of a platform that can safely collect/classify/

analyze/share/trade/manage patient's sensitive

medical/health databased on trust between participants.

In addition, we provide not only simple medical/health data,

but also various medical and healthcare services using data.

 
7766.png

Li⁺@C60 Lithium Endohedral Fullerene

The core technology of the Molecular Medical & Healthcare Platform presented by the CDBIO Foundation is molecular sensor technology using lithium Endohedral Fullerene. Li⁺@C60 (Lithium Endohedral Fullerene), successfully commercialized for the first time in the world through joint research by Dr. Eunsang Kwon, a world-renowned scholar at the Research and Analytical Center for Giant Molecules in Japan (Tohoku Univ), and Dr. Yasuhiko Kasama, CEO of Idea International, is the most important type of Endohedral Metallofullerene as a newly emerging carbon nano material.

 

Lithium Endohedral Fullerene has the lowest energy level among substances developed or discovered so far.

Energy levels are the energy values of quantized states where electrons formed in quantum mechanics, such as atoms, molecules, or solid materials, can exist.

 

Lithium Endohedral Fullerene is a state-of-the-art diagnostic sensor that can accurately diagnose disease-causing substances in molecular units, and it can measure the energy level of disease-causing substances to check the occurrence and progress of disease.

 
1112.jpg

Molecular Diagnostic Kits

1113.jpg

Molecular Diagnostic Systems

1114.jpg

Molecular Synthesis Therapeutics

MANAGEMENT

TEAM

1.jpg
7.jpg
6.jpg
2.jpg
3.jpg

Founder

Baek Kyoungjin

CEO

Lee Jiman

General Director

Kim Kihoon

Executive Director

Jeon Minho

Planning Director

Hahm Younghwi

Present) CDBIO Limited. Founder

CDBIO Inc. CEO
Past) SJK Inc. Deputy CEO
Smart Innovation Inc. CEO
Mediascape Inc. Deputy CEO

Present) CDBIO Limited. CEO

Past) SJK Inc. General Manager

Bexco Inc. Manager

Present) CDBIO General Director
Domestic Foul Produce Inc.

Management Consultant
Mars LP Inc. General Director

Present) CDBIO Inc. Executive Director

Starbucket Executive Director & Audit

Past) Quartz Inc. Executive Director

Theme IM Inc. CEO

Present) CDBIO CSO
Past) Smart Innovation Inc. CSO

Mediascape Inc. CSO

AK217 Inc. CEO
   Digitul Chosun Ilbo Media Team Lead
   Incomm Inc. AE

TEAM

ADVISOR

Financial Advisory

Kim Juil

Legal Advisory

Jo Sanggi

Investment Advisory

Jang Sanghyeon

Medical Verification Advisory

Kim Yeongyu

Present) KOTRA-affiliated

Invest Korea CEO

Present) Korean Academy of

Clinical Health Chairman
Past) International Organization

UIA Korea Representative

(Union of International Association)
   USA ILRS FDA Research Institute Head

International Licensing Research Solutions LLC

Present) Dadam LLC.

Vice President

Lawfirm Joong Bu Law Director
Korea Industrial Development Institute

(Researcher at the Industry Office)

Present) Kim Juil Tax Accounting

Firm President
Gangseo-gu Office

Local Taxation Examiner
   Gunpo-si Local Taxation Examiner
   UJU Electronics Co. Ltd

Tax Consultation

PARTNERS

 
 

TOKEN SUMMARY

776655.png

MAX SUPPLY

1,000,000,000 MCD

SALE

50,000,000 MCD

Etherscan

TOKEN DISTRIBUTION BUDGET

15%

5%

Token Sale

Operation

30%

Ecosystem

30%

Marketing

& Liquidity

10%

5%

Partners

5%

Team/Advisor

Reserve

 
66677.jpg

ROADMAP

77776655.png